Since July 1, the prices of six hypertension and epilepsy medicines of Novartis have been reduced by as much as 87 percent.
The price reduction of Novartis hypertension medicines ranges from 15 to 61 percent, covering Valsartan, Valsartan + Hydrochlorothiazide, Valsartan + Amlodipine, and Valsartan + Amlodipine + Hydrochlorothiazide.
The price reduction of the Novartis epilepsy medicines Carbamazepine and Oxcarbazepine, on the other hand, ranges from 10 to 87 percent
“Novartis is implementing our Legacy Pricing initiative in the Philippines in line with our shared goal of providing Filipinos with affordable access to sustainable healthcare,” said Jugo Tsumura, country president and managing director of Novartis Healthcare Philippines.
Legacy Pricing aims to support the implementation of the Universal Health Care Act and provide Filipinos across socioeconomic segments access to essential and innovative medicines.
“Our mission is reimagining medicine to improve and extend people’s lives. To achieve our purpose, we work to improve access and affordability of our medicines,” said Tsumura.